MONTREAL, June 9 — A team of researchers led by Dr. André Veillette, a medical professor at the Université de Montréal, has made a discovery that sheds light on why some cancer treatments stop working. The study, published in the journal Nature, centers on SLAMF6, a molecule found on the surface of immune cells that can prevent T cells from mounting a strong attack against tumors.
SLAMF6 works differently from many other molecules that suppress immune responses, as it can activate itself directly on the surface of T cells, sending signals that weaken the body’s defenses. This mechanism is a previously unknown one, and understanding it could be key to developing more effective cancer treatments.
Dr.
Veillette and his team at the Montreal Clinical Research Institute (IRCM) have been studying this molecule and its role in cancer immunotherapy. Current cancer immunotherapies, including PD1 and PDL1 inhibitors, work by removing inhibitory signals created by tumors, but a significant number of patients either fail to respond or eventually develop resistance.
The researchers found that SLAMF6 can be a major obstacle to the success of these treatments, as it can suppress the immune response even when other inhibitory signals are removed. The team has made a breakthrough in overcoming the effects of SLAMF6, by creating monoclonal antibodies designed to stop the molecule from binding to itself and triggering its suppressive signals. These newly developed antibodies have shown promising results in laboratory testing, and the researchers believe they could become the foundation of a new treatment for cancer patients.
The discovery has the potential to bring new hope to patients who have not responded to existing treatments.
The development of antibodies that can block SLAMF6 is a major step forward in the fight against cancer, and the team is eager to continue their research. As the field of cancer immunotherapy continues to evolve, breakthroughs like this one offer a glimpse of a future where more effective treatments are available to patients.
The research team’s focus on understanding the mechanisms that allow cancers to evade the immune system is crucial to developing new and more effective treatments.
By studying the role of SLAMF6 and other molecules that suppress immune responses, scientists can gain a deeper understanding of how to boost the body’s natural defenses against cancer. As research in this area continues to advance, patients and their families can look forward to the possibility of more effective treatments and better outcomes.
Consult your doctor for medical advice.
